20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Sana Biotechnology Inc (SANA) operates in the BIOTECHNOLOGY industry and is headquartered in Seattle, United States with about 142 employees. Its market capitalization is roughly $928 million. In the fiscal year ended 2025-12-31, SANA reported $0M in revenue and ($244M) in net income.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | ($13M) | ($15M) | ($31M) | ($28M) | ($18M) | ($10M) | ($4M) | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($208M) | ($191M) | ($273M) | ($293M) | ($273M) | ($357M) | ($286M) | ($141M) | ($8M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — |
| Net Income | ($212M) | ($244M) | ($267M) | ($283M) | ($266M) | ($344M) | ($279M) | ($131M) | ($13M) |
| Net Margin % | — | — | — | — | — | — | — | — | — |
| EBITDA | ($201M) | ($231M) | ($249M) | ($259M) | ($257M) | ($346M) | ($280M) | ($139M) | ($13M) |
| Earnings Per Share (EPS) | $-0.78 | $-0.96 | $-1.16 | $-1.46 | $-1.41 | $-2.07 | $-1.49 | $-0.70 | $-0.07 |
| Shares Outstanding (M) | 296M | 253M | 231M | 195M | 188M | 166M | 188M | 187M | 187M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $15M | $0M |
| Gross Profit | — | ($2M) | ($3M) | — | ($3M) | ($4M) | $8M | ($4M) |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($65M) | ($38M) | ($61M) | ($44M) | ($95M) | ($51M) | ($51M) | ($62M) |
| Operating Margin % | — | — | — | — | — | — | -332.9% | — |
| Net Income | ($64M) | ($47M) | ($59M) | ($42M) | ($94M) | ($49M) | ($49M) | ($60M) |
| Net Margin % | — | — | — | — | — | — | -321.1% | — |
| EBITDA | ($61M) | ($45M) | ($56M) | ($39M) | ($48M) | ($46M) | ($43M) | ($56M) |
| Earnings Per Share (EPS) | $-0.22 | $-0.17 | $-0.23 | $-0.16 | $-0.39 | $-0.21 | $-0.21 | $-0.25 |
| Shares Outstanding (M) | 296M | 277M | 253M | 260M | 238M | 238M | 236M | 235M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($132M) | ($144M) | ($223M) | ($254M) | ($290M) | ($251M) | ($138M) | ($86M) | ($13M) |
| Capital Expenditures (CapEx) | $3M | $1M | $33M | $20M | $21M | $30M | $24M | $26M | $0M |
| Free Cash Flow (FCF) | ($135M) | ($145M) | ($257M) | ($274M) | ($311M) | ($281M) | ($162M) | ($112M) | ($14M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($33M) | ($37M) | ($33M) | ($29M) | ($33M) | ($49M) | ($47M) | ($52M) |
| Capital Expenditures (CapEx) | $2M | $0M | $1M | $0M | $0M | $0M | $0M | $4M |
| Free Cash Flow (FCF) | ($34M) | ($38M) | ($34M) | ($29M) | ($33M) | ($49M) | ($48M) | ($56M) |
| FCF Margin % | — | — | — | — | — | — | -311.5% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $432M | $417M | $501M | $565M | $823M | $1.1B | $730M | $415M | $34M |
| Cash & Cash Equivalents | $57M | $72M | $128M | $134M | $177M | $253M | $125M | $80M | $31M |
| Total Liabilities | $277M | $256M | $251M | $278M | $323M | $401M | $1.2B | $558M | $48M |
| Total Debt (Short + Long-Term) | $15M | $15M | $13M | $13M | $12M | $9M | $4M | $1M | $0M |
| Total Shareholders' Equity | $155M | $161M | $251M | $288M | $499M | $729M | ($421M) | ($143M) | ($13M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SANA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms